Saturday 7 November 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024.
- Revenue
- −32.5%
- EPS
- +82.0%
- Free cash flow
- −54.3%
Quarter to June 2026, against a year earlier
0.60
0.32
−34.78%
Follow SXTP
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 4 |
+8 more TTM periods Free account |
| 115.54% | 152.76% | 130.53% | 188.40% | ||
| (194.65%) | (124.23%) | (138.45%) | (117.83%) | ||
ROIC |
(348.64%) | (352.89%) | (771.41%) | (2,193.93%) | |
Return on Tangible Assets |
(347.76%) | (170.40%) | (233.45%) | (191.57%) | |
Average Days of Receivables |
170.33 | 93.21 | 131.99 | 180.23 | |
Free Cash Flow per Share |
(3.41) | (4.78) | (10.55) | (7.49) | |
Free Cash Flow |
(9.06) | (8.25) | (7.07) | (6.88) | |
Capital Expenditures |
(0.29) | (0.25) | (0.22) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(255.23%) | (102.04%) | (115.28%) | (81.33%) | |
Accounts Receivable Turnover |
2.82 | 3.19 | 2.83 | 2.74 | |
Accounts Payable Turnover |
0.65 | 0.60 | 0.63 | 0.95 | |
Inventory Turnover |
0.82 | 0.94 | 1.42 | 2.02 | |
Average Days of Payables |
646.79 | 683.76 | 681.39 | 514.57 | |
Days of Inventory on Hand |
466.15 | 418.55 | 306.73 | 194.91 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
196.19% | 153.38% | 149.46% | 148.46% | |
Selling, General and Administrative Expense of Revenue |
538.56% | 490.23% | 445.62% | 473.80% | |
Share Based Compensation of Revenue |
18.87% | 16.49% | 19.86% | 16.82% | |
Interest Coverage |
(1,105.21) | (1,073.32) | (994.68) | (1,330.46) | |
Operating CF/Net income |
1.07 | 1.01 | 0.89 | 0.82 | |
Depreciation/Fixed assets |
1.18 | 1.04 | 1.05 | 1.10 | |
Capex/Depreciation |
(1.00) | (0.94) | (0.84) | (0.35) | |
Revenue per Share |
0.46 | 0.76 | 2.10 | 1.49 | |
Operating CF per Share |
(3.31) | (4.63) | (10.22) | (7.40) | |
Capex per Share |
(0.11) | (0.15) | (0.33) | (0.10) | |
Capex to Sales |
0.24 | 0.19 | 0.15 | 0.06 |
Columns are period end dates · fundamentals updated 26 Oct 2026